This systematic review of six RCTs and two meta-analyses explored the relationship between T2DM and the magnitude reduction of cardiovascular outcomes, such as cardiovascular mortality, MACE, and CHF hospitalizations of SGLT2 inhibitors compared to placebo, in a population with eGFR >30 ml/min/1.73 m2 with or without the use of diuretics, average age >60 years, irrespective of sex and ethnicity, range of HbA1c 7-8.9%, and BMI between 26-37 kg/m2. Here, SLC5A2 is linked to type 2 diabetes mellitus.